The effect of pulsed light therapy on meibomian gland dysfunction patients

Blepharitis Pulsed Light therapy (BPL) for dry eye secondary to meibomian gland dysfunction(MGD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003051

Enrollment

Registered

2018-07-31

Start date

2016-05-20

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Patients with MGD received 3 sessions of IPL treatment of 3 weeks interval. Eye shields are placed to protect the participant’s eyes and cooling gel is applied to the treatment area.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adult over 19 years of age 2. Patient diagnosed with meibomian gland dysfunction 3. Fitzpatrick skin type I-IV 4. Those who voluntarily agreed to participate in the study

Exclusion criteria

Exclusion criteria: 1. Fitzpatrick skin type V-VI 2. Sun or artificial tanning within 4 weeks prior to the study participation 3. Dermatologic condition that does not allow to receive light therapy 4. Ocular or eyelid surgery within 6 months prior to study participation 5. Ocular infection or inflammation 6. Precancerous lesion or skin cancer in the treatment area 7. Systemic infection or immunosuppressive status 8. Medical conditions associated with photosensitivity such as herpes simplex virus infection, systemic lupus erythematosis and porphyria 9. Medications which can cause photosensitivity such as isoretinoin, tetracycline, and St. John’s warts 10. Radiotherapy history within 1 year prior to study participation, or planned radiotherapy within 8 weeks from study conclusion 11. Chemotherapy history within 8 weeks prior to study participation, or planned chemotherapy within 8 weeks from study conclusion 12. Topical medication use on the treatment area or a new drug history within 3 months prior to study participation 13. Change in previous drug regimen within 3 months prior to study participation 14. Pregnant or lactating 15. Monocular 16. Those who the investigators consider inappropriate to participate in the study

Design outcomes

Primary

Measure	Time frame
Change in meibomian gland function	—

Secondary

Measure	Time frame
Change in tear cytokine;Change in corneal and conjunctival staining;Change in tear break-up time;Change in Ocular Surface Disease Index	—

Countries

Korea, Republic of

Contacts

Public ContactKyoung Yul Seo

Yonsei University Health System, Severance Hospital

seoky@yuhs.ac+82-2-2228-3570

Outcome results